Gene Biotherapeutics, Inc. (CRXM)
USD 0.0
(9900.0%)
USD 0.0
(9900.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2022 | - USD | 0.0% |
| 2021 | - USD | 100.0% |
| 2020 | -1.26 Million USD | -61.83% |
| 2019 | -778.82 Thousand USD | 29.2% |
| 2018 | -450.02 Thousand USD | 46.61% |
| 2017 | -2.06 Million USD | 26.97% |
| 2016 | -2.82 Million USD | 9.15% |
| 2015 | -3.1 Million USD | 12.84% |
| 2014 | -3.56 Million USD | 46.1% |
| 2013 | -6.6 Million USD | 18.43% |
| 2012 | -8.03 Million USD | -6.65% |
| 2011 | -6.92 Million USD | 13.4% |
| 2010 | -6.76 Million USD | -31.44% |
| 2009 | -7.79 Million USD | 70.08% |
| 2008 | -15.63 Million USD | 9.45% |
| 2007 | -24.63 Million USD | -33.96% |
| 2006 | -17.67 Million USD | -229.73% |
| 2005 | -5.43 Million USD | -1495.49% |
| 2004 | -349.52 Thousand USD | 15.66% |
| 2003 | -414.42 Thousand USD | 91.53% |
| 2002 | -4.89 Million USD | -431.89% |
| 2001 | -919.62 Thousand USD | 44.74% |
| 2000 | -1.66 Million USD | -108.97% |
| 1999 | -796.41 Thousand USD | -114.15% |
| 1998 | -3.27 Million USD | 308.54% |
| 1997 | -4.89 Million USD | 32.71% |
| 1996 | -4.48 Million USD | 33.65% |
| 1995 | -6.16 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2022 FY | - USD | 0.0% |
| 2021 FY | - USD | 100.0% |
| 2020 Q1 | -152.46 Thousand USD | 8.9% |
| 2020 FY | - USD | -61.83% |
| 2020 Q3 | -388.32 Thousand USD | -60.28% |
| 2020 Q4 | -477.28 Thousand USD | -22.91% |
| 2020 Q2 | -242.28 Thousand USD | -58.92% |
| 2019 FY | - USD | 29.2% |
| 2019 Q1 | -227.03 Thousand USD | 0.0% |
| 2019 Q2 | -224.88 Thousand USD | 0.95% |
| 2019 Q3 | -159.54 Thousand USD | 29.05% |
| 2019 Q4 | -167.35 Thousand USD | -4.9% |
| 2018 FY | - USD | 46.61% |
| 2017 Q1 | -635.17 Thousand USD | 17.96% |
| 2017 FY | - USD | 26.97% |
| 2016 Q3 | -1.01 Million USD | -67.35% |
| 2016 Q1 | -420.73 Thousand USD | -138.72% |
| 2016 FY | - USD | 9.15% |
| 2016 Q4 | -774.21 Thousand USD | 23.79% |
| 2016 Q2 | -607.06 Thousand USD | -44.29% |
| 2015 Q4 | -176.25 Thousand USD | 85.16% |
| 2015 FY | - USD | 12.84% |
| 2015 Q1 | -605.17 Thousand USD | -25.02% |
| 2015 Q2 | -1.13 Million USD | -87.75% |
| 2015 Q3 | -1.18 Million USD | -4.51% |
| 2014 Q1 | -1.43 Million USD | -94.42% |
| 2014 Q2 | -952.84 Thousand USD | 33.6% |
| 2014 FY | - USD | 46.1% |
| 2014 Q3 | -709.72 Thousand USD | 25.52% |
| 2014 Q4 | -484.07 Thousand USD | 31.79% |
| 2013 Q3 | -1.67 Million USD | 17.18% |
| 2013 FY | - USD | 18.43% |
| 2013 Q1 | -2.16 Million USD | -29.13% |
| 2013 Q2 | -2.02 Million USD | 6.63% |
| 2013 Q4 | -738.07 Thousand USD | 56.0% |
| 2012 Q4 | -1.67 Million USD | 10.24% |
| 2012 FY | - USD | -6.65% |
| 2012 Q3 | -1.87 Million USD | -1.03% |
| 2012 Q2 | -1.85 Million USD | 31.39% |
| 2012 Q1 | -2.69 Million USD | -58.68% |
| 2011 Q2 | -2.16 Million USD | -17.54% |
| 2011 Q1 | -1.84 Million USD | 45.59% |
| 2011 Q4 | -1.7 Million USD | 10.04% |
| 2011 FY | - USD | 13.4% |
| 2011 Q3 | -1.89 Million USD | 12.6% |
| 2010 Q3 | -142.3 Thousand USD | 95.55% |
| 2010 FY | - USD | -31.44% |
| 2010 Q1 | -1.87 Million USD | 85.54% |
| 2010 Q2 | -3.19 Million USD | -70.4% |
| 2010 Q4 | -3.38 Million USD | -2277.98% |
| 2009 Q2 | 2.86 Million USD | -56.19% |
| 2009 Q3 | -4.07 Million USD | -242.04% |
| 2009 Q4 | -12.99 Million USD | -218.82% |
| 2009 Q1 | 6.54 Million USD | 251.18% |
| 2009 FY | - USD | 70.08% |
| 2008 FY | - USD | 9.45% |
| 2008 Q2 | -6.16 Million USD | 2.6% |
| 2008 Q3 | -5.39 Million USD | 12.42% |
| 2008 Q4 | -4.33 Million USD | 19.73% |
| 2008 Q1 | -6.32 Million USD | 5.53% |
| 2007 Q4 | -6.69 Million USD | -12.14% |
| 2007 Q3 | -5.97 Million USD | 5.73% |
| 2007 Q2 | -6.33 Million USD | -12.45% |
| 2007 FY | - USD | -33.96% |
| 2007 Q1 | -5.63 Million USD | 17.81% |
| 2006 FY | - USD | -229.73% |
| 2006 Q4 | -6.85 Million USD | -28.5% |
| 2006 Q3 | -5.33 Million USD | -51.68% |
| 2006 Q2 | -3.51 Million USD | -30.87% |
| 2006 Q1 | -2.68 Million USD | 0.0% |
| 2005 Q2 | -35.53 Thousand USD | -7.29% |
| 2005 FY | - USD | -1495.49% |
| 2005 Q3 | -114.12 Thousand USD | -221.19% |
| 2005 Q1 | -33.11 Thousand USD | 50.3% |
| 2004 Q3 | -79.21 Thousand USD | 6.76% |
| 2004 Q4 | -66.63 Thousand USD | 15.87% |
| 2004 Q2 | -84.95 Thousand USD | -4.01% |
| 2004 FY | - USD | 15.66% |
| 2004 Q1 | -81.68 Thousand USD | 21.21% |
| 2003 FY | - USD | 91.53% |
| 2003 Q4 | -103.67 Thousand USD | -15.94% |
| 2003 Q2 | -88.19 Thousand USD | 3.74% |
| 2003 Q1 | -91.62 Thousand USD | 36.89% |
| 2003 Q3 | -89.41 Thousand USD | -1.38% |
| 2002 Q1 | -123.23 Thousand USD | 5.12% |
| 2002 Q2 | -136.44 Thousand USD | -2.26% |
| 2002 Q3 | -4.5 Million USD | -3472.54% |
| 2002 Q4 | -144.38 Thousand USD | 96.78% |
| 2002 FY | - USD | -431.89% |
| 2001 Q1 | -145.61 Thousand USD | 71.22% |
| 2001 Q3 | -147.73 Thousand USD | -11.22% |
| 2001 Q2 | -113.16 Thousand USD | 7.83% |
| 2001 FY | - USD | 44.74% |
| 2001 Q4 | -129.87 Thousand USD | 12.09% |
| 2000 Q4 | -504.44 Thousand USD | 3.37% |
| 2000 Q2 | -238.51 Thousand USD | -100.66% |
| 2000 Q1 | -541.82 Thousand USD | 106174.94% |
| 2000 FY | - USD | -108.97% |
| 2000 Q3 | -518.14 Thousand USD | -117.24% |
| 1999 FY | - USD | -114.15% |
| 1999 Q4 | -365.77 Thousand USD | 0.0% |
| 1998 Q3 | -1.07 Million USD | -75.96% |
| 1998 FY | - USD | 308.54% |
| 1998 Q1 | -400 Thousand USD | 1466.67% |
| 1998 Q2 | -600 Thousand USD | -46.34% |
| 1997 FY | - USD | 32.71% |
| 1997 Q4 | -300 Thousand USD | -50.6% |
| 1997 Q3 | -1.51 Million USD | 60.16% |
| 1997 Q2 | -600 Thousand USD | 16.67% |
| 1997 Q1 | -600 Thousand USD | 53.85% |
| 1996 FY | - USD | 33.65% |
| 1996 Q1 | 200 Thousand USD | 0.0% |
| 1996 Q2 | 200 Thousand USD | 0.0% |
| 1996 Q3 | -5.11 Million USD | -2658.54% |
| 1996 Q4 | -1.4 Million USD | 74.59% |
| 1995 Q4 | 200 Thousand USD | 0.0% |
| 1995 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| America Great Health | -447.29 Thousand USD | 100.0% |
| Evolutionary Genomics, Inc. | -913.47 Thousand USD | 100.0% |
| Innovation1 Biotech Inc. | -5.68 Million USD | 100.0% |
| Point of Care Nano-Technology, Inc. | -73.41 Thousand USD | 100.0% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | 100.0% |